[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"periodontal-attachment-loss\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:periodontal-attachment-loss":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,44,68,97,124,149,174,194],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100539890","hyaluronic-acid-and-polynucleotides-for-supra-bony-defects-100539890",false,"NCT06309719","Hyaluronic Acid and Polynucleotides for Supra-bony Defects","Characterizing the Healing of Periodontal Supra-bony Defects Treated With Hyaluronic Acid and Polynucleotides","Inclusion Criteria:\n\n* Systemically healthy males and females ≥18 years old\n* Stage III or IV periodontitis (Papapanou, Sanz et al. 2018)\n* Presence of supra-bony periodontal defects (i.e., defects where the base of the pocket is located coronal to the alveolar crest and characterized by a predominantly horizontal pattern of tissue destruction) confirmed clinically and radiographically at a minimum of two and a maximum of four adjacent teeth and with a probing pocket depth (PPD) \\> 5 mm, following non-surgical periodontal therapy (NSPT). If \\>4 adjacent teeth exhibited the above clinical and radiographic conditions, the four adjacent teeth showing the greatest overall loss of periodontal attachment were included. Wisdom teeth and second molars will not be considered for the study.\n\nIf defect presents with an intrabony component, this should be ≤2 mm.\n\n* Non-surgical periodontal treatment (step 1 and 2) completed within the previous 4 months\n* Full-mouth bleeding score (FMBS) and full-mouth plaque score (FMPS) ≤20%\n\nExclusion Criteria:\n\n* Teeth with degree III mobility\n* Multi-rooted teeth with grade ≥2 furcation involvement\n* Heavy smokers (≥10 cigarettes a day)\n* Untreated caries or endodontic lesions or abscesses on the teeth involved in the surgery\n* Previous periodontal surgery in the area selected for the study\n* History of conditions requiring prophylactic antibiotic coverage prior to invasive dental procedures (e.g., mitral valve prolapse, artificial heart)\n* Antibiotic or anticoagulant therapy during the month preceding the baseline exam.\n* History of alcohol or drug abuse\n* Medical history that includes uncontrolled diabetes or hepatic or renal diseases, or other serious medical conditions that can have a negative impact on the periodontal condition\n* In treatment with medications that can severely affect bone metabolism and blood clot formation (e.g., anticoagulants, long-term corticosteroids, bisphosphonates, immunosuppressants)\n* Self-reported pregnancy or lactation.","ALL","18 Years",{"count":19,"type":20},24,"ESTIMATED","INTERVENTIONAL",[23],"NA","The goal of this pilot study is to describe the early wound healing molecular events and the vascularization pattern associated with the treatment of supra-bony defects with access flap alone or in association with a combined formulation of hyaluronic acid and polydeoxyribonucleotides gel.",[26,27,28,29,30],"Periodontal Diseases","Wound Heal","Periodontal Inflammation","Periodontal Pocket","Periodontal Attachment Loss","RECRUITING","2026-07-01",{"date":34,"type":35},"2026-07-02","ACTUAL",{"date":37,"type":35},"2024-10-21",{"date":39,"type":20},"2026-12",{"name":41,"class":42},"Queen Mary University of London","OTHER",2,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":52,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":21,"phases":55,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":67},"100593995","prf-as-adjunct-to-subgingival-instrumentation-in-step-2-periodontal-therapy-100593995","NCT07013682","PRF as Adjunct to Subgingival Instrumentation in Step 2 Periodontal Therapy","Platelet Rich Fibrin Adjunctive to Non-surgical Periodontal Therapy: a 6-month Split-mouth Randomized Controlled Clinical Trial","PRFSTEP2","Inclusion Criteria:\n\n* Men and women aged ≥ 18 years\n* Periodontitis stage II-IV, grade A\u002FB\u002FC, generalized\n* Presence of at least 20 teeth (excluding wisdom teeth)\n* Absence of removable dentures\n* Patients willing to provide written informed consent and to complete the 6- month study follow-up\n\nExclusion Criteria:\n\n* Patients already participating in other clinical trials\n* Periodontal treatment in the previous 12 months\n* Antibiotic treatment 3 months prior to study entry\n* Antibiotic prophylaxis required for dental treatment\n* Current use of any medication that may affect the clinical features of periodontitis\n* Pregnant\u002Flactating\n* Any condition that prevents venipuncture\n* Not willing to venous puncture\n* Current cancer treatment\n* History of radiation in the head-neck area",true,{"count":54,"type":20},20,[23],"Periodontitis is characterized by a chronic, multifactorial inflammatory process driven by dysbiotic plaque biofilms. It is recognized as the most common chronic inflammatory non-communicable disease in humans. The advanced and severe forms of periodontitis have an estimated prevalence of 7.4%, while milder forms can affect up to 50% of the population.\n\nIf left untreated, periodontitis can lead to tooth loss. However, it is largely preventable and treatable with mechanical non-surgical periodontal therapy. To improve periodontal healing and thus clinical attachment gain after non-surgical therapy, adjunctive bioactive formulations such as enamel matrix derivatives, sodium hypochlorite, locally delivered antimicrobials, or hyaluronic acid have recently been proposed. However, these agents are non-autologous formulations and expensive.\n\nPlatelet-rich fibrin (PRF) acts as a scaffold that inhibits the early migration of epithelial cells into the periodontal tissues. Its regenerative properties are primarily due to its ability to promote angiogenesis. This ability is attributed to the 3D fibrin matrix, which can simultaneously transport several cytokines and growth factors. These include vascular endothelial growth factor (VEGF), insulin growth factor (IGF), transforming growth factor β1 (TGF-β1) and platelet-derived growth factor (PDGF). PRF further shows antibacterial properties and accelerates soft tissue healing. So far PRF is not routinely used in periodontal non-surgical therapy.\n\nThe aim of this 6-month, split-mouth randomized clinical trial including 20 patients is to test whether PRF can improve the results after non-surgical therapy.",[58,28,30],"Periodontitis","2026-06-30",{"date":34,"type":35},{"date":62,"type":35},"2025-05-01",{"date":64,"type":20},"2027-12-24",{"name":66,"class":42},"University of Bern",1,{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":4,"eligibilityCriteria":74,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":75,"targetDuration":4,"studyType":21,"phases":77,"briefSummary":78,"conditions":79,"keywords":82,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":67},"100505212","clinical-effectiveness-of-biologic-agents-as-an-adjunct-to-non-surgical-periodontal-therapy-of-intrabony-defects-100505212","NCT05858411","Clinical Effectiveness of Biologic Agents as an Adjunct to Non-surgical Periodontal Therapy of Intrabony Defects","Evaluation of the Efficacy of rhPDGF, L-PRF and EMD as an Adjunct to Non-surgical Periodontal Therapy of Intrabony Defects: a Randomized Controlled Clinical Trial","Inclusion Criteria:\n\n* Patients with a diagnosis of periodontitis stage III or IV (grades A to C),\n* non-smokers or former smokers who quit at least 1 year ago, and\n* had not received any periodontal treatment in the 3 months prior to recruitment;\n* Presence of at least 1 Infrabony defect (PPD ≥ 5 mm with infrabony defect depth of ≥3mm at screening radiograph);\n* One and two wall infrabony defects at screening radiograph and periodontal charting.\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Presence of uncontrolled systemic diseases that could affect treatment outcomes such as diabetes mellitus with an HbA1C\\>7%, rheumatoid arthritis or any form of immunosuppression;\n* Subjects requiring antibiotic prophylaxis;\n* 3-wall infrabony defects;\n* Patients that had received systemic or local delivery of antibiotic therapy 6 weeks before enrollment;\n* Presence of furcation defect;\n* Chronic intake of NSAIDs or steroids, currently;\n* Patients undergoing orthodontic treatment, having removable prosthetic appliances, pregnancy, tumors of the oral cavity or the presence of any psychiatric condition that could affect participation.",{"count":76,"type":20},88,[23],"The aim of the present study is to clinically and radiographically compare the efficacy of recombinant human platelet-derived growth factor (rhPDGF), Leukocyte-Platelet Rich Fibrin (L-PRF) and Enamel Matrix Derivatives (EMD) in intrabony defects following minimally invasive non surgical peridoontal therapy (MINST).\n\nThis study will be designed as a randomized clinical trial of 12-month duration. A total of 88 patients (each with a single infrabony defect) will be recruited and randomly equally distributed into 4 groups: an experimental group treated with MINST and rhPDGF, a second group treated with MINST + L-PRF, a third group treated with MINST and EMD and and a control group treated with MINST alone.\n\nEach defect will be treated with an ultrasonic scaler with dedicated thin tips for supra- and subgingival debridement associated with hand instrumentation under local anesthesia. Caution will be taken to preserve the stability of soft tissues. Following MINST experimental and control sites will be randomly chosen. The test sites will be treated by inserting a collagen plug soaked for at least 15 minutes in a 1.5cc solution containing hPDGF-BB. In the second group the infrabony defects will be treated with MINST and L-PRF. In the third group the infrabony defects will be treated with MINST and EMD. The control group will be treated with MINST alone.\n\nPre- and post-treatment clinical measurements were performed by an examiner blinded to the treatment modalities using a graded periodontal probe (HuFriedy UNC 15). Before the treatment and at 6 and 12 months post-treatment, all patients were examined by measuring the clinical attachment level, probing depth, gingival recession, full-mouth plaque score and bleeding on probing.\n\nStandardized radiographs of selected study sites will be taken at baseline and at the 6 and 12 months follow-up visits using the long-cone technique with a customized holder and a thermoplastic occlusal reference to allow reproducible positioning. All radiographs will be analysed by a dedicated dental software (Carestream Dental LLC Atlanta, GA, USA) to make linear measurements. The defect bone level (DBL), the defect angle (DA), the intra- and suprabony components of the defect and the radiographic defect area (RDA) will be evaluated.",[26,30,80,81],"Pocket, Periodontal","Intrabony Periodontal Defect",[83,84,85,86,87],"rhPDGF","Growth factors","Periodontal regeneration","L-PRF","Enamel Matrix Derivatives","2026-05-25",{"date":90,"type":35},"2026-05-28",{"date":92,"type":35},"2023-01-08",{"date":94,"type":20},"2027-09-01",{"name":96,"class":42},"G. d'Annunzio University",{"id":98,"slug":99,"hasResults":11,"nctId":100,"briefTitle":101,"officialTitle":102,"acronym":4,"eligibilityCriteria":103,"healthyVolunteers":52,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":104,"targetDuration":4,"studyType":106,"phases":4,"briefSummary":107,"conditions":108,"keywords":110,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":67},"100634170","characterization-of-jak1-and-jak2-activation-in-gingival-tissues-during-homeostasis-and-periodontitis-100634170","NCT07536204","Characterization of JAK1 and JAK2 Activation in Gingival Tissues During Homeostasis and Periodontitis","Unraveling the Role of JAK1 and JAK2 Pathway in Periodontitis: Drivers of Immunopathology and Possible Therapeutic Targets","Inclusion Criteria:\n\n* Adults\n* Sistemically healthy\n\nExclusion Criteria:\n\n* Active Maliganancy\n* History of radiation to the head-neck region\n* Chemotherapy or radiation within the last 5 years\n* History of hepatitis B\u002FC or HIV infection\n* Autoimmune diseases\n* Diagnosis of diabetes\n* Pregnancy or lactation\n* More than 3 hospitalizations over the last 3 years\n* Use of systemic antibiotics over the last 3 months\n* Use of systemic corticosteroids or immunosuppressants over the last 3 months\n* Use of cytokine therapy over the last 3 months\n* Use of large doses of pre\u002Fprobiotic supplements over the last 3 months\n* Smoke more than 10 cigarettes per day",{"count":105,"type":20},30,"OBSERVATIONAL","The goal of this observational study is to examine JAK1\u002F2 pathway activation in gingival tissues from adults with healthy gingiva and those with inflamed gingiva (periodontitis). The main question it aims to answer is:\n\nIs the JAK1\u002F2 pathway overactivated in periodontitis compared to health?\n\nParticipants with healthy gingiva and periodontitis will donate gingival tissue to study the JAK1\u002F2 pathway. All participants wil receive diagnosis and treatment of the gingival condition.",[58,26,28,109,30],"Gingival Diseases",[111,112,58,113,114],"JAK1","JAK2","Gingiva","Inflammation","2026-04-10",{"date":117,"type":35},"2026-04-17",{"date":119,"type":35},"2023-06-01",{"date":121,"type":20},"2027-03-31",{"name":123,"class":42},"University of Chile",{"id":125,"slug":126,"hasResults":11,"nctId":127,"briefTitle":128,"officialTitle":129,"acronym":4,"eligibilityCriteria":130,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":131,"targetDuration":4,"studyType":21,"phases":132,"briefSummary":133,"conditions":134,"keywords":137,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":147,"locationsCount":67},"100627245","adjunctive-diode-laser-therapy-in-non-surgical-periodontal-therapy-100627245","NCT07446127","Adjunctive Diode Laser Therapy in Non-Surgical Periodontal Therapy","Evaluation of the Effect of Adjunctive Diode Laser Therapy in Mechanical Scaling and Root Surface Debridement in Non-Surgical Periodontal Therapy","Inclusion Criteria:\n\n1. Systemically healthy patients\n2. Each patient should have more than 20 teeth remaining, and at least 5 teeth per quadrant\n3. Each patient presented ≥ 30% of sites involved\n4. At least 2 teeth with a probing depth of ≥ 5 mm in each quadrant, with evident radiographic bone loss.\n\nExclusion Criteria:\n\n1. History of systemic diseases affecting the periodontium\n2. Smokers and alcoholic patients\n3. Use of medication within the last 6 months, which might affect the periodontal status\n4. Pregnant and lactating women\n5. Patients who had any periodontal treatment ≤ 12 months before the examination.",{"count":54,"type":20},[23],"The goal of this clinical trial is to evaluate the efficacy of adjunctive application of diode laser to mechanical, non-surgical root surface debridement in patients attending periodontal office. The main question it aims to answer is:\n\nTo compare the clinical effectiveness of adjunctive application of a 940-nm diode laser with root surface debridement to the effectiveness of root surface debridement alone.\n\nThis study is a split-mouth design, where each quadrant will be randomly allocated to one of the following groups:\n\nControl group (root surface debridement - RsD): scaling and root planing alone. Laser group (RsD + laser): scaling and root planing with adjunctive diode laser therapy Quadrants will be randomly allocated to the treatment groups",[135,136,30],"Periodontal Disease","Periodontal Pockets",[138,139],"diode laser","non surgical periodontal treatment","2026-02-25",{"date":142,"type":35},"2026-03-03",{"date":144,"type":35},"2026-01-01",{"date":146,"type":20},"2026-12-31",{"name":148,"class":42},"Tel Aviv University",{"id":150,"slug":151,"hasResults":11,"nctId":152,"briefTitle":153,"officialTitle":154,"acronym":4,"eligibilityCriteria":155,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":156,"targetDuration":4,"studyType":21,"phases":158,"briefSummary":159,"conditions":160,"keywords":161,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":166,"lastUpdatePostDateStruct":167,"startDateStruct":169,"completionDateStruct":171,"leadSponsor":173,"locationsCount":43},"100556233","hyaluronic-acid-and-octenidine-gel-as-an-adjunct-to-non-surgical-periodontal-treatment-100556233","NCT06522438","Hyaluronic Acid and Octenidine Gel as an Adjunct to Non-surgical Periodontal Treatment","Early Healing Dynamics and Microbial Changes Following the Use of a Novel Thermosensitive Gel With Hyaluronic Acid and Octenidine as an Adjunct to Non-surgical Periodontal Treatment","Inclusion Criteria:\n\n* Male or female aged 18 and above\n* Engaged patients presenting with a Full Mouth Plaque Score (FMPS) of ≤ 20% within the 6 weeks prior to enrolment, or exhibiting a ≥ 50% reduction in plaque score from the initial screening visit.\n* Periodontitis stage III\u002FIV (grades A to C) with at least one site per quadrant with PPD ≥5mm, bleeding on probing and attachment loss ≥5mm\n* Willing to sign informed consent and comply with study procedures\n\nExclusion Criteria:\n\n* Know hypersensitivity and\u002For allergy to any of the product's component (as per user leaflet)\n* Self-reported pregnancy or lactation\n* Smoking (current or in past 5 years), including e-cigarettes\u002Fvaping\n* Medical history including diabetes mellitus or other serious medical\u002F psychiatric conditions or transmittable diseases that according to the investigator may increase the risk associated with study participation\n* History of conditions requiring prophylactic antibiotic coverage prior to invasive dental procedures or\u002Fand systemic antibiotic therapy during the 3 months preceding the baseline evaluation\n* In chronic treatment with anti-inflammatory (including corticosteroids), anticoagulants\u002Fantiplatelets (including aspirin), immunosuppressants or other medication that can severely impact wound healing\n* History of alcohol or drug abuse\n* Subgingival professional mechanical plaque removal (excluding not-extensive subgingival debridement as judged by the examining clinician) and\u002For surgical periodontal treatment within the last 12 months\n* Other severe acute or chronic medical or psychiatric condition or psychological disorder, including limited mental capacity or language skills such that study information could not be understood, informed consent could not be obtained, or simple instructions could not be followed, or any additional conditions which, in the judgement of the investigator, would make the subject inappropriate for entry into this trial",{"count":157,"type":20},26,[23],"This parallel-group, pilot study will test the hypothesis that the adjunctive use of a thermosensitive gel containing Hyaluronic Acid (HA) and Octenidine to non-surgical periodontal treatment (NSPT) will be able to modulate the early wound healing events. This will be assessed through the expression of specific gingival crevicular fluid markers, as well as by changes in gingival blood flow (assessed by laser speckle contrast imaging), bacterial load, soft tissues contour, clinical parameters and patient-reported outcomes.\n\nThe study will involve up to 26 patients and will take place at the Centre for Oral Clinical Research (COCR), at the Institute of Dentistry, Faculty of Medicine and Dentistry, Queen Mary University of London under The Royal London Dental Hospital, Barts Health NHS Trust. Patients will be randomised to receive either NSPT alone or NSPT+ HA and Octenidine gel, and will be followed up to 3 months after treatment.\n\nThe study will consist of 7- 8 visits.",[58,27,29,28,30],[162,163,164,165],"Hyaluronic Acid","Octenidine","Biomarkers","Non-surgical periodontal treatment","2026-02-03",{"date":168,"type":35},"2026-02-05",{"date":170,"type":35},"2025-06-03",{"date":172,"type":20},"2027-12-31",{"name":41,"class":42},{"id":175,"slug":176,"hasResults":11,"nctId":177,"briefTitle":178,"officialTitle":179,"acronym":4,"eligibilityCriteria":180,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":181,"targetDuration":4,"studyType":21,"phases":183,"briefSummary":184,"conditions":185,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":186,"lastUpdatePostDateStruct":187,"startDateStruct":189,"completionDateStruct":190,"leadSponsor":192,"locationsCount":67},"100525535","modified-widman-flap-vs-fibre-retention-osseous-resective-surgery-100525535","NCT06123000","Modified Widman Flap vs Fibre Retention Osseous Resective Surgery","Modified Widman Flap (MWF) vs Fibre Retention Osseous Resective Surgery (FibReORS): A Randomized, Controlled, Clinical Trial.","Inclusion Criteria:\n\n* Age ≥ 18 years;\n* Patients affected by periodontitis;\n* No systemic disease or pregnancy;\n* No systemic antibiotic therapy in 6 months preceding the enrollment;\n* Smoking ≤ 20 cigarettes\u002Fday;\n* Full-mouth plaque score (FMPS) and full- mouth bleeding score (FMBS) ≤ 15%;\n* Residual periodontal pocket ≥5 mm with bleeding on probing at posterior natural teeth;\n* Experimental pocket associated with a detectable infrabony defect ≤ 3mm at x-ray;\n* No history of periodontal surgery at the experimental site.\n\nExclusion Criteria:\n\n* Undetectable cemento-enamel junction (CEJ) at experimental teeth;\n* Severe furcation involvement (class II and III);\n* Abutment for prosthetic rehabilitation;\n* Periodontal Pockets associated with infrabony defect \\>3 mm;\n* Horizontal bone loss higher than 1\u002F3 of the root length at experimental teeth;\n* Severe tooth mobility at baseline (class 2 or 3).",{"count":182,"type":20},36,[23],"The treatment of periodontitis should be carried out in an incremental manner, first by achieving adequate patient's oral hygiene practices and risk factor control during the first step of therapy and then, during the second step of therapy, by professional elimination (reduction) of supra and subgingival biofilm and calculus.\n\nIf the endpoints of therapy (no periodontal pockets \\>4 mm with bleeding on probing, BoP, or deep pockets ≥5 mm) have not been achieved, the third step of therapy should be implemented.\n\nIn fact, residual pockets following step 1 and 2 of periodontal treatment are associated with increased risk of periodontal disease progression in the long-term as reported by Claffey \\& Egelberg in1995. Residual probing depth (PPD) ≥5 mm after active therapy is a risk factor for disease progression and tooth loss during supportive periodontal therapy (SPT), suggesting that additional treatment of residual pockets is strongly recommended.\n\nThe third step of treatment includes the following interventions: repeated subgingival instrumentation, access flap periodontal surgery, resective periodontal surgery, regenerative periodontal surgery.\n\nIn case of residual pockets associated with shallow-moderate infrabony defects at posterior teeth, where both regenerative therapy and non-surgical re-instrumentation are usually not indicated, access flap procedures (i.e., the Modified Widman Flap, MWF) and the Osseous Resective Surgery (ORS) are considered two of the most viable options.\n\nThe value of these surgical techniques has been tested over the years by different clinical trials, and the choice of a surgical approach still relies mainly on the decision-making process of the surgeon, since the long-term outcomes of the different periodontal surgical procedures are similar, as highlighted by a recent systematic review.\n\nNevertheless, one the main criticism that have been moved against ORS, lies on the fact that the side effects (i.e., gingival recessions) seem to be more severe for ORS surgery, when compared with MWF.\n\nIn the early 2000s, Carnevale proposed the Fibre Retention Osseous Resective Surgery (FibReORS), an approach that leads to a more conservative bone resection to eliminate infrabony defects and establish a positive bony architecture than the conventional ORS. Indeed, this one, based on the histological findings by Gargiulo et al. (1961), uses the level of the connective tissue attachment - rather than the bottom of the osseous defect - as the reference to apply the principles of ORS.\n\nTwo randomized clinical trials demonstrated that FibReORS is similarly effective as ORS for PPD reduction with less final gingival recessions (REC), clinical attachment loss (CAL) patient morbidity.\n\nNevertheless, no studies have ever directly compared FibreORS with MWF. Therefore, the aim of this randomized clinical trial (RCT) is to compare the efficacy of FibReORS versus MWF in the treatment of periodontal pockets associated with infrabony defects ≤3 mm at posterior natural teeth.\n\nObjectives\n\nThe experimental hypothesis is:\n\nFibReORS is superior to MWF in achieving PPD closure (PPD \\\u003C4 mm without BoP) at posterior teeth associated with shallow-moderate infrabony defects.",[58,29,30],"2025-04-07",{"date":188,"type":35},"2025-04-10",{"date":37,"type":35},{"date":191,"type":20},"2026-10-21",{"name":193,"class":42},"University of Florence",{"id":195,"slug":196,"hasResults":11,"nctId":197,"briefTitle":198,"officialTitle":199,"acronym":4,"eligibilityCriteria":200,"healthyVolunteers":52,"sex":16,"minAge":17,"maxAge":201,"enrollmentInfo":202,"targetDuration":4,"studyType":21,"phases":204,"briefSummary":205,"conditions":206,"keywords":207,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":211,"lastUpdatePostDateStruct":212,"startDateStruct":214,"completionDateStruct":216,"leadSponsor":218,"locationsCount":67},"100564059","effectiveness-of-srp-lipo-curcumin-gel-for-the-treatment-of-stage-iii-periodontitis-100564059","NCT06624241","Effectiveness of SRP+ Lipo-curcumin Gel for the Treatment of Stage III Periodontitis.","Clinical Evaluation of Lipo-Curcumin Gel in Association with SRP for the Treatment of Stage III Periodontitis: a Randomized and Controlled Clinical Trial.","Inclusion Criteria:\n\n* Patients with a diagnosis of periodontitis stage III (grades A to C)\n* on-smokers or former smokers who quit at least 1 year ago, and had not received any periodontal treatment in the 3 months prior to recruitment\n* FMPS \\\u003C 20% at baseline\n* Furcation not involved\n* Not Pregnant or Lactating\n* Signed informed consent\n\nExclusion Criteria:\n\n* Presence of uncontrolled systemic diseases that could affect treatment outcomes such as diabetes mellitus with an HbA1C\\>7%, rheumatoid arthritis or any form of immunosuppression\n* Patients that had received systemic or local delivery of antibiotic therapy 6 weeks before enrollment\n* Chronic intake of NSAIDs or steroids, currently","80 Years",{"count":203,"type":20},40,[23],"The aim of the present study is to clinically and radiographically compare the effectivness of Scaling and Root Plannig (SRP) in association with lipo-curcumin gel (LC) respect SRP+ lipo-gel (L), SRP+ discharged (D) gel and SRP alone.\n\nThis study will be designed as a randomized clinical trial of 12-month duration. A total of 40 patients will be recruited and randomly equally distributed into 4 groups: an experimental group treated with SRP + LC, a first control group treated with SRP + L, a second control group treated with SRP+D and a third control group SRP alone.\n\nEach defect will be treated with an ultrasonic scaler with dedicated thin tips for supra- and subgingival debridement associated with hand instrumentation under local anesthesia. Caution will be taken to preserve the stability of soft tissues. Following SRP, experimental and control sites will be randomly chosen. The test sites will be t filled with a Lipo-Curcumin gel and sealed with cyanoacrylate. In the first control group the defects will be be filled with a Lipo gel and sealed with cyanoacrylate. In the second control sites he pocket defect will be filled with a discharged gel and sealed with cyanoacrylate, in the third control group SRP alone will be performed.\n\nPre- and post-treatment clinical measurements were performed by an examiner blinded to the treatment modalities using a graded periodontal probe (HuFriedy UNC 15). Before the treatment and at 6 and 12 months post-treatment, all patients were examined by measuring the clinical attachment level, probing depth, gingival recession, full-mouth plaque score and bleeding on probing.",[26,29,30],[208,209,210,58],"Curcumin","SRP","Liposome","2024-09-30",{"date":213,"type":35},"2024-10-02",{"date":215,"type":35},"2024-06-12",{"date":217,"type":20},"2025-09",{"name":96,"class":42}]